Clinical Trial Update: This Study is an Open-lable, Phase I Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. [Phase 1]

View source ↗

Summary

This is an open-label Phase I study evaluating the safety, feasibility, cytokinetics, and preliminary efficacy of GC511B in DLL3-positive relapsed/refractory sm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• GC511B

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Relapsed/Refractory Small Cell Lung Cancer | Phase 1 | Status: NOT_YET_RECRUITING